Low-lying spectrum of the Y-string three-quark potential using hyper-spherical coordinates

We calculate the energies of three-quark states with definite permutation symmetry (i.e. of SU(6) multiplets) in the N=0,1,2 shells, confined by the Y-string three-quark potential. The exact Y-string potential consists of one, so-called three-string term, and three angle-dependent two-string terms. Due to this technical complication we treat the problem at three increasingly accurate levels of approximation: 1) the (approximate) three-string potential expanded to first order in trigonometric functions of hyper-spherical angles; 2) the (approximate) three-string potential to all orders in the power expansion in hyper-spherical harmonics, but without taking into account the transition(s) to two-string potentials; 3) the exact minimal-length string potential to all orders in power expansion in hyper-spherical harmonics, and taking into account the transition(s) to two-string potentials. We show the general trend of improvement %convergence of these approximations: The exact non-perturbative corrections to the total energy are of the order of one per cent, as compared with approximation 2), yet the exact energy differences between the $[20,1^{+}], [70,2^{+}], [56,2^{+}], [70,0^{+}]$-plets are shifted to 2:2:0.9, from the Bowler and Tynemouth separation rule 2:2:1, which is obeyed by approximation 2) at the one per cent level. The precise value of the energy separation of the first radial excitation ("Roper") $[56^{\prime},0^{+}]$-plet from the $[70,1^{-}]$-plet depends on the approximation, but does not become negative, i.e. the "Roper" remains heavier than the odd-parity $[70,1^{-}]$-plet in all of our approximations.Comment: 19 pages, 6 figure

Quantum three-body system in D dimensions

The independent eigenstates of the total orbital angular momentum operators for a three-body system in an arbitrary D-dimensional space are presented by the method of group theory. The Schr\"{o}dinger equation is reduced to the generalized radial equations satisfied by the generalized radial functions with a given total orbital angular momentum denoted by a Young diagram $[\mu,\nu,0,...,0]$ for the SO(D) group. Only three internal variables are involved in the functions and equations. The number of both the functions and the equations for the given angular momentum is finite and equal to $(\mu-\nu+1)$.Comment: 16 pages, no figure, RevTex, Accepted by J. Math. Phy

Calculation of the photoionization with de-excitation cross sections of He and helium-like ions

We discuss the results of the calculation of the photoionization with de-excitation of excited He and helium-like ions Li$^{+}$ and B$^{3+}$ at high but non-relativistic photon energies $\omega$. Several lower $^{1}S$ and $^{3}S$ states are considered. We present and analyze the ratios $R_{d}^{+\ast}$ of the cross sections of photoionization with de-excitation, $\sigma_{(d)}^{+\ast}(\omega)$, and of the photo-ionization with excitation, $\sigma ^{+\ast}(\omega)$. The dependence of $R_{d}^{+\ast}$ on the excitation of the target object and the charge of its nucleus is presented. Apart to theoretical interest, results obtained can be verified using such long living excited state as $2^{3}S$ of He.Comment: 10 pages, 6 table

State Dependent Effective Interaction for the Hyperspherical Formalism

The method of effective interaction, traditionally used in the framework of an harmonic oscillator basis, is applied to the hyperspherical formalism of few-body nuclei (A=3-6). The separation of the hyperradial part leads to a state dependent effective potential. Undesirable features of the harmonic oscillator approach associated with the introduction of a spurious confining potential are avoided. It is shown that with the present method one obtains an enormous improvement of the convergence of the hyperspherical harmonics series in calculating ground state properties, excitation energies and transitions to continuum states.Comment: LaTeX, 16 pages, 8 ps figure

Benchmark Test Calculation of a Four-Nucleon Bound State

In the past, several efficient methods have been developed to solve the Schroedinger equation for four-nucleon bound states accurately. These are the Faddeev-Yakubovsky, the coupled-rearrangement-channel Gaussian-basis variational, the stochastic variational, the hyperspherical variational, the Green's function Monte Carlo, the no-core shell model and the effective interaction hyperspherical harmonic methods. In this article we compare the energy eigenvalue results and some wave function properties using the realistic AV8' NN interaction. The results of all schemes agree very well showing the high accuracy of our present ability to calculate the four-nucleon bound state.Comment: 17 pages, 1 figure

Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms:a systematic review conducted to inform new NICE DG30 diagnostic guidance

__Background:__ This study has attempted to assess the effectiveness of quantitative faecal immunochemical tests (FIT) for triage of people presenting with lower abdominal symptoms, where a referral to secondary care for investigation of suspected colorectal cancer (CRC) is being considered, particularly when the 2-week criteria are not met. __Methods:__ We conducted a systematic review following published guidelines for systematic reviews of diagnostic tests. Twenty-one resources were searched up until March 2016. Summary estimates were calculated using a bivariate model or a random-effects logistic regression model. __Results:__ Nine studies are included in this review. One additional study, included in our systematic review, was provided as 'academic in confidence' and cannot be described herein. When FIT was based on a single faecal sample and a cut-off of 10 μg Hb/g faeces, sensitivity estimates indicated that a negative result using either the OC-Sensor or HM-JACKarc may be adequate to rule out nearly all CRC; the summary estimate of sensitivity for the OC-Sensor was 92.1%, based on four studies, and the only study of HM-JACKarc to assess the 10 μg Hb/g faeces cut-off reported a sensitivity of 100%. The corresponding specificity estimates were 85.8% (95% CI 78.3-91.0%) and 76.6%, respectively. When the diagnostic criterion was changed to include lower grades of neoplasia, i.e. the target condition included higher risk adenoma (HRA) as well as CRC, the rule-out performance of both FIT assays was reduced. __Conclusions:__ There is evidence to suggest that triage using FIT at a cut-off around 10 μg Hb/g faeces has the potential to correctly rule out CRC and avoid colonoscopy in 75-80% of symptomatic patients. Systematic review registration: PROSPERO 4201603772

Acute ECG ST-segment elevation mimicking myocardial infarction in a patient with pulmonary embolism

Pulmonary embolism is a common cardiovascular emergency, but it is still often misdiagnosed due to its unspecific clinical symptoms. Elevated troponin concentrations are associated with greater morbidity and mortality in patients with pulmonary embolism. Right ventricular ischemia due to increased right ventricular afterload is believed to be underlying mechanism of elevated troponin values in acute pulmonary embolism, but a paradoxical coronary artery embolism through opened intra-artrial communication is another possible explanation as shown in our case report

Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study

Background: Lumacaftor/ivacaftor (LUM/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (CF) ≥1 year of age. To assess the impact of early LUM/IVA initiation on CF disease progression, a 6-year observational study leveraging data from existing CF patient registries is being conducted in children with CF homozygous for F508del (F/F genotype) who were aged 2 through 5 years at treatment initiation. Here we present interim results from this study focusing on data from the European CF Society Patient Registry (ECFSPR). Methods: The LUM/IVA cohort included children in the ECFSPR who started LUM/IVA between 15 January 2019 and 31 December 2020. Longitudinal trends in growth parameters, pulmonary exacerbations, hospitalizations, safety outcomes, and other effectiveness outcomes in the LUM/IVA cohort were compared to those in two modulator-naïve cohorts: (i) matched concurrent cohort heterozygous for F508del and a minimal function mutation (F/MF concurrent comparator cohort) and (ii) matched concurrent cohort with the F/F genotype from countries without commercial access to LUM/IVA as of 2020 (F/F concurrent comparator cohort). Results: The LUM/IVA cohort matched to the F/MF concurrent comparator cohort had 681 children and the LUM/IVA cohort matched to the F/F concurrent comparator cohort had 183 children. LUM/IVA cohorts had increases in body mass index percentiles relative to the matched F/MF and F/F concurrent comparator cohorts (mean difference in change from baseline: 8.4 [95% CI: 5.5, 11.3] and 11.8 [95% CI: 5.9, 17.7], respectively). Increases in height and weight percentiles were also observed in the LUM/IVA cohort relative to the F/MF and F/F concurrent comparator cohorts. Reductions in pulmonary exacerbations and hospitalizations relative to baseline and the F/F concurrent comparator cohort were seen in 2021. Conclusions: This interim analysis showed favorable trends in clinical outcomes, including growth parameters, pulmonary exacerbations, and hospitalizations, suggesting an early beneficial effect of LUM/IVA treatment in children aged 2 through 5 years at treatment initiation

Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo

Introduction: Severe asthma is a rare disease in children, for which three biologicals, anti-immunoglobulin E, anti-interleukin-5 and anti-IL4RA antibodies, are available in European countries. While global guidelines exist on who should receive biologicals, knowledge is lacking on how those guidelines are implemented in real life and which unmet needs exist in the field. In this survey, we aimed to investigate the status quo and identify open questions in biological therapy of childhood asthma across Europe. Methods: Structured interviews regarding experience with biologicals, regulations on access to the different treatment options, drug selection, therapy success and discontinuation of therapy were performed. Content analysis was used to analyse data. Results: We interviewed 37 experts from 25 European countries and Turkey and found a considerable range in the number of children treated with biologicals per centre. All participating countries provide public access to at least one biological. Most countries allow different medical disciplines to prescribe biologicals to children with asthma, and only a few restrict therapy to specialised centres. We observed significant variation in the time point at which treatment success is assessed, in therapy duration and in the success rate of discontinuation. Most participating centres intend to apply a personalised medicine approach in the future to match patients a priori to available biologicals. Conclusion: Substantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident